Morningstar

Coloplast AS Class B COLO B

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 862.60 −12.40 (1.42%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Coloplast: Stays a Step Ahead of Competition Thanks to Innovative New Products

Debbie S. Wang

Though inflationary pressures have been alleviated to some extent, Coloplast’s ongoing launches of key new products should damp operating margin until fiscal 2026. After taking another look at how these product introductions are going, we’re leaving our fair value estimate intact. Despite the incremental investment needed to support the commercialization of these new products, we think Coloplast’s advances in ostomy, continence care, and advanced wound technologies reinforce the foundation of the firm’s wide economic moat.

Read Full Report

Price vs Fair Value

View History
COLO B is trading at a 843% premium.
Price
DKK 862.60
Fair Value
DKK 972.00
Uncertainty
Medium
1-Star Price
DKK 2,318.70
5-Star Price
DKK 839.70
Economic Moat
Lqmxd
Capital Allocation
Qvxsrllyqc

Bulls Say, Bears Say

Bulls

Because of aging populations in developed countries, the incidence of colorectal disease is growing. Independent of age, the incidence of inflammatory bowel disease is also on the rise.

Bears

Now that Coloplast has already shifted most of its manufacturing to low-cost geographies, gains in gross margin may not be so easy to achieve.

Show More

Trading Information

Previous Close Price
DKK 875.00
Day Range
DKK 860.20–877.20
52-Week Range
DKK 689.20–977.60
Bid/Ask
DKK 862.40 / DKK 862.80
Market Cap
DKK 194.12 Bil
Volume/Avg
112,072 / 164,429

Key Statistics

Price/Earnings (Normalized)
38.76
Price/Sales
7.37
Dividend Yield (Trailing)
2.43%
Dividend Yield (Forward)
2.43%
Total Yield
2.43%

Company Profile

Coloplast AS is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Large Growth
Total Number of Employees
16,019
Website
https://www.coloplast.com

Competitors

Valuation

View More
Metric
COLO B
BSX
CTEC
Price/Earnings (Normalized)
 38.7637.9118.12
Price/Book Value
 11.756.103.46
Price/Sales
 7.378.212.60
Price/Cash Flow
 56.4431.7016.62
Price/Earnings
COLO B
BSX
CTEC

Financial Strength

Metric
COLO B
BSX
CTEC
Quick Ratio
 0.530.951.21
Current Ratio
 0.851.612.26
Interest Coverage
 8.818.663.44
Quick Ratio
COLO B
BSX
CTEC

Profitability

Metric
COLO B
BSX
CTEC
Return on Assets (Normalized)
 11.10%9.33%7.42%
Return on Equity (Normalized)
 35.43%17.03%16.55%
Return on Invested Capital (Normalized)
 15.15%11.85%10.83%
Return on Assets
COLO B
BSX
CTEC

Medical Instruments & Supplies Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
LcyygppthcWwd$171.3 Bil
 Becton Dickinson & Co
BDX
VzplmqrstJpnvtjr$68.9 Bil
 Alcon Inc
ALC
DsdtljgFbsslx$48.1 Bil
 ResMed Inc
RMD
QqgxbthxqVcwchnt$34.3 Bil
 Coloplast AS ADR
CLPBY
CxstfyqptmTbhx$28.7 Bil
 West Pharmaceutical Services Inc
WST
FbxvpyqhgdRffz$21.5 Bil
 The Cooper Companies Inc
COO
JrfmytkjMgmchb$21.1 Bil
 Hologic Inc
HOLX
RrdcdlnPnvpwjp$18.6 Bil
 Baxter International Inc
BAX
KglblqqcGwngc$18.5 Bil
 Align Technology Inc
ALGN
ThnzvncbXjjxd$18.0 Bil

Sponsor Center